Skip to main content

Table 3 Immunohistochemistry analysis of whole tumor and IM of pretreatment tumor biopsies

From: A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors

Cancer TypeBOR%PD-L1+%CD8+ ALLa%FoxP3+ ALLaCD8/FoxP3 ALLa%CB8+ IMb%FoxP3+ IMb%CD137+ IMbCD8/FoxP3 IMb
NSCLCPR0.001.701.720.999.961.4514.216.87
SCCHNPD0.006.895.381.2813.286.488.592.05
SCCHNSD0.0017.161.749.86NENENENE
SCCHNSD10.0013.694.982.75NENENENE
SCCHNSD0.0012.239.431.314.6810.0510.371.46
  1. Marker-positive cells are reported as a percent of evaluated cells
  2. aALL: The region encompassing the tumor and extending up to the leading edge, but not outside the tumor-normal interface
  3. bIM: The region extending from 500 μm outside the leading edge of the tumor to 500 μm inside
  4. BOR Best overall response, NE Not evaluable, NSCLC Non–small-cell lung cancer, PD Progressive disease, PD-L1 Programmed cell death-ligand 1, PR Partial response, SCCHN Squamous cell cancer of head and neck, SD Stable disease